TITLE:
Reinduction Chemotherapy with Gemtuzumab Ozogamicin and Intermediate/High-Dose Cytarabine: A Single-Center Experience
AUTHORS:
Sohsuke Meshitsuka, Mitsuo Hori, Shoichi Mitsuhashi, Yasushi Okoshi, Hiroshi Kojima
KEYWORDS:
Gemtuzumab Ozogamicin; AML; Reinduction; Salvage
JOURNAL NAME:
Open Journal of Blood Diseases,
Vol.4 No.1,
March
18,
2014
ABSTRACT: We performed a retrospective analysis of 9 patients with acute myeloid
leukemia (AML) treated with gemtuzumab ozogamicin (GO) plus cytarabine as a
salvage regimen (GO reinduction) for patients who did not achieve complete
remission (CR) after the first cycle of induction chemotherapy or at first
relapse. Cases of AML secondary to myelodysplastic syndrome or
myeloproliferative disorder were included. CR was achieved in 6 of 9 patients,
and 2 of 6 responders became long-term survivors. No
non-responders survived longer than 6 months. Toxicity was mild, and the median
duration of myelosuppression was less than 30 days. Stomatitis, nausea and
sepsis occurred as non-hematological adverse events. Although our sample size
was too small to permit definitive conclusions, GO reinduction should be considered
for patients who relapse or do not achieve CR after the first cycle of
induction chemotherapy. Some AML subtypes may respond more robustly than
others, and further investigation is warranted.